RIVERAIN TECHNOLOGIES CLEARREAD™ CT SELECTED BY THE VA'S LUNG PRECISION ONCOLOGY PROGRAM FOR EARLY LUNG CANCER DETECTION – Yahoo Finance
ClearRead CT Is the Only Thoracic Imaging Interpretation Solution with Clear Visual Intelligence™ Using Unique Suppression Technology
MIAMISBURG, Ohio, Nov. 15, 2022 /PRNewswire/ — Riverain Technologies, the pioneer of Clear Visual Intelligence™ (CVI™) for chest imaging interpretation, was selected by the Veterans Health Administration (VHA) to provide its unique imaging interpretation solution, ClearRead™ CT, to the Veteran Affair’s (VA) Lung Precision Oncology Program (LPOP). With ClearRead CT, the VA’s LPOP patients’ care will now include CVI with vessel suppression for chest imaging interpretation alongside standard CT images for interpretation. Improving diagnostic accuracy and earlier intervention for better patient outcomes, ClearRead CT with CVI has shown a 29% reduction in missed nodules and a 26% reduction in nodule search time.
Riverain Technologies is the pioneer of Clear Visual Intelligence™ for chest imaging interpretation.
About 8,000 veterans are diagnosed and treated by the VA for lung cancer each year, with an estimated 900,000 veterans at risk for lung cancer due to age, smoking, and environmental exposures during and after military service. LPOP chose ClearRead CT to help improve the lung cancer survival rate for veterans across the U.S., which aligns with Riverain’s mission to reduce delayed cardio-thoracic disease diagnoses from the nationwide statistic of 1 in 3 to none in 3.
ClearRead CT with CVI is the only imaging interpretation solution available with suppression technology that allows radiologists to see beyond obstructions to clearly, confidently, and quickly detect cardio-thoracic diseases with Certainty of Search™ (CoS™). It removes the web of vessels in the chest CT image, allowing radiologists to see clearly and decide confidently. In addition, automated precision measurements with ClearRead CT lead to improved repeatability and consistency of imaging interpretation across different radiology readers, times of day, and workload. This is important given the alarming levels of radiology burnout and talent shortage.
“This initiative aligns with our mission of building a bold future of radiology where delayed or missed diagnoses don’t happen,” says Steve Worrell, CEO, Riverain Technologies. “Accurate imaging interpretation will make a critical difference for veterans and their families, and arming VA radiologists with Clear Visual Intelligence supports the advances the VA is making in lung cancer detection and care. We are pleased the VA recognized this opportunity and selected Riverain as the solution provider for LPOP.”
The VA selected ClearRead CT as a new tool for LPOP to proactively detect lung cancer at 22 LPOP VA hub locations and 87 spoke sites across the country. The VA desires a proven, consistent, supportable enterprise radiology computer-aided detection (CAD) system to provide the same standard of care across its system. The VA’s contract with Riverain is for ClearRead CT software, hardware, licensing, interfacing, training, and implementation.
About Riverain Technologies
Riverain Technologies is on a mission to revolutionize radiology by changing 1 in 3 delayed cardio-thoracic disease diagnoses to none in 3. Using unique suppression technology, the company’s ClearRead imaging interpretation solutions with Clear Visual Intelligence™ (CVI™) create an unobstructed view within the existing workflow so radiologists can focus on what matters, precisely characterize, and report findings. Imaging interpretation with CVI™ moves radiologists beyond standard background-impaired imaging interpretation to allow focus on the actionable data to correctly and quickly detect cardio-thoracic diseases with newfound Certainty of Search™ (CoS™). For more information: https://www.riveraintech.com/.
Media Contacts:
David Truncer
dtruncer@riveraintech.com
Patty Pologruto
patty@greymattermarketing.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/riverain-technologies-clearread-ct-selected-by-the-vas-lung-precision-oncology-program-for-early-lung-cancer-detection-301677708.html
SOURCE Riverain
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit. The full data comes from the entire 11-week evaluation period, including a 5-week placebo run-off following the initial 6-week treatment period. The data exhibited consistent and statistically significant treatment-period benefits in measures of particular importance in painful diabetic neuropathy (also k
Biogen had been a sinking ship following its Alzheimer’s flop, but positive results in September have changed the company’s trajectory.
The faster people are diagnosed, the better the chance that medical intervention can help stave off the progression.
The attack on the Liberian-flagged oil tanker Pacific Zircon happened Tuesday night off the coast of Oman, the Mideast-based defense official said.
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
(Bloomberg) — US President Joe Biden and key European leaders are urging caution after a rocket struck a Polish village just over the border from Ukraine, as doubts grow over whether Russia was to blame and, if so, whether it had been an accident.Most Read from BloombergUkraine Latest: Biden Says Missile Likely Not Fired From RussiaTrump Makes His 2024 Run Official, Defies Calls to Move OnPoland Says Russian-Made Missile Hit Territory and Killed Two PeopleBiden Says Unlikely Rocket That Hit Pol
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Positive Preliminary Results from Combination Therapy of EPI-7386 and Enzalutamide On October 28, 2022, ESSA Pharma Inc (NASDAQ:EPIX) announced multiple poster presentations at the 29th Annual Prostate Cancer Foundation Scientific Retreat, including an update on the Phase 1/2 Study of EPI-7386 in combination with
The world is experiencing a quiet yet accelerating collapse in male fertility, according to a paper published Tuesday in the journal Human Reproduction Update. The study found sperm counts fell by more than 51 percent between 1973 and 2018. And while sperm counts have been dropping for decades, the decline rate appears to be speeding up.…
The Russians have lost control over several units in the occupied part of Luhansk Oblast; cases of extortion of money to avoid mobilisation are also recorded in Luhansk Oblast. Source: General Staff of the Armed Forces of Ukraine on Facebook, information as of 18:00 on 15 November Quote: "As a result of fire damage in the area of the settlement of Kreminna, Luhansk Oblast, the Russian invaders have lost control over several units.
The ink is not yet dry on Amazon's $4 billion acquisition of OneMedical, but in the meantime, the online services giant is making one more move into telehealth, and into medical services overall, on its own steam. The company today is taking the wraps off of Amazon Clinic, which Amazon describes as a virtual health "storefront": users can search for, connect with and pay for telehealth care, addressing a variety of conditions that are some of the more popular for telehealth consultations today. Amazon Clinic is initially launching in 32 states in the U.S. It does not work with health insurance and this point, and overall pricing will vary depending on providers, conditions and location.
Police in Kyiv Oblast have posted a video showing a Russian missile falling in one of the settlements. The missile damaged about 10 houses. Source: Andrii Niebytov, the head of the National Police of Ukraine in Kyiv Oblast, on Telegram Quote from Niebytov: "10 houses have been damaged in the occupiers' attack on one of the districts of Kyiv Oblast.
The agency is developing a plan with measures that could include requiring doctors to notify authorities of cronobacter cases.
Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA.
(Bloomberg) — US President Joe Biden said a rocket that struck a village in Poland near the Ukraine border was unlikely to have been fired from Russia, comments that may limit the risk of a major escalation in tensions over the incident.Most Read from BloombergUkraine Latest: Biden Says Missile Likely Not Fired From RussiaTrump Makes His 2024 Run Official, Defies Calls to Move OnPoland Says Russian-Made Missile Hit Territory and Killed Two PeopleBiden Says Unlikely Rocket That Hit Poland Was Fi
Infinity Pharmaceuticals Inc (NASDAQ: INFI) reported an update from its MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic triple-negative breast cancer (TNBC) patients. Sixty-two patients were enrolled and evaluable for safety, and 57 (were evaluable for efficacy, with a median duration of follow-up of 10.0 months. Encouraging one-year progression-free survival rates in MARIO-3 1L TNBC study regardless of PD-L1 status. 52% increase in one-ye
(Bloomberg) — President Joe Biden said a rocket that struck a village in Poland near the Ukraine border was unlikely to have been fired from Russia, comments that may limit the risk of a major escalation in tensions over the incident.Most Read from BloombergUkraine Latest: Biden Says Missile Likely Not Fired From RussiaTrump Makes His 2024 Run Official, Defies Calls to Move OnPoland Says Russian-Made Missile Hit Territory and Killed Two PeopleBiden Says Unlikely Rocket That Hit Poland Was Fired
Halozyme's under-the-skin technology helps deliver some of the biggest moneymaking injections, fueling booming growth and prospects for much more. HALO stock is surging.
The combination of addiction-drug makers could tap into billions of dollars in settlement and federal funds aimed at expanding access to treatment.
Oracle Cerner and Labcorp have partnered to manage hospital laboratories in 10 states, including Kansas.
Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease.